WO2017017696A1 - Process for the preparation of lumacaftor - Google Patents
Process for the preparation of lumacaftor Download PDFInfo
- Publication number
- WO2017017696A1 WO2017017696A1 PCT/IN2016/050250 IN2016050250W WO2017017696A1 WO 2017017696 A1 WO2017017696 A1 WO 2017017696A1 IN 2016050250 W IN2016050250 W IN 2016050250W WO 2017017696 A1 WO2017017696 A1 WO 2017017696A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- process according
- acid
- mixtures
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 Cc1ccc(NC(C2(CC2)c(cc2)cc(O3)c2OC3(F)F)=O)nc1-c1cccc(*)c1 Chemical compound Cc1ccc(NC(C2(CC2)c(cc2)cc(O3)c2OC3(F)F)=O)nc1-c1cccc(*)c1 0.000 description 5
- OGDSGFSPCQGELG-UHFFFAOYSA-N N#CCc(cc1)cc(O2)c1OC2(F)F Chemical compound N#CCc(cc1)cc(O2)c1OC2(F)F OGDSGFSPCQGELG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Definitions
- the present invention relates to novel process for the preparation of lumacaftor useful for treating a cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease such as cystic fibrosis.
- CFTR cystic fibrosis transmembrane conductance regulator
- the present invention provides processes for the preparation of lumacaftor and its pharmaceutically acceptable salts.
- the present invention provides a process for the preparation of lumacaftor, that may include the steps of:
- X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described below.
- Another aspect of the present invention encompasses processes for the preparation of lumacaftor that may include the steps of:
- X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described below.
- the present invention provides a process for the preparation of a compound of formula II as shown in scheme.
- the present invention provides a process for the preparation of formula II that may include the step of converting a compound of formula lib to compound of formula II, where X is any halogen.
- the present invention provides additional processes for the preparation of a com ound of formula II as shown in scheme.
- the present invention provides a process for the preparation of a compound of formula II that may include the step of converting compound of formula lid to compound of formula II.
- the present invention provides a process for the preparation of a compound of formula III as shown in scheme.
- the present invention provides a process for the preparation of a compound of formula III that may include the steps of halogenating the compound of formula Hid with halogenating agent to get a compound of formula III.
- X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described below.
- the present invention relates to process for the preparation of CFTR corrector lumacaftor or its pharmaceutically acceptable salts.
- LG suitable "leaving groups”
- halogens e.g., fluorine, chlorine, bromine, iodine
- methanesulfonyloxy p- toluenesulfonyloxy, trifluoromethanesulfonyloxy, nonafluorobutanesulfonyloxy, (4- bromo-benzene)sulfonyloxy, (4-nitro-benzene)sulfonyloxy, (2-nitro-benzene)- sulfonyloxy, (4-isopropyl-benzene)sulfonyloxy, (2,4,6-tri-isopropyl-benzene)- sulfonyloxy, (2,4,6-trimethyl-benzene)sulfonyloxy, (4-tertbutyl-benzene)sulfonyloxy, benzenesulfonyloxy
- halogens e.g., flu
- Suitable alkoxy groups useful within the context of the present invention include, but are not limited to, methoxy, ethoxy, propoxy, 1 -methylethoxy, butoxy, 1 , 1 -dimethyl ethoxy, and 1-methylpropoxy.
- An alkoxy group may be substituted by one or more halogens, or may be unsubstituted.
- methoxy, ethoxy, and trifluoromethoxy were found to be particularly effective as leaving groups.
- X means any halogen. Suitable halogens useful within the context of the present invention include, but are not limited to, fluorine, chlorine, bromine, and iodine.
- carboxylic acid protecting group means a chemical moiety that protects a carboxylic acid residue from unwanted reaction.
- Suitable carboxylic acid protecting groups useful with in the context of the present invention include, but are not limited to, alkyl ester such as methyl ester, ethyl ester, t-butyl ester; arakyl ester such as benzyl ester ; silyl ester, and oxazoline.
- pharmaceutically acceptable salt is well known and understood in the art and refers to salts of pharmaceutically active agents which are suitable for use in contact with the tissues of humans and lower animals without undue adverse effects (e.g., toxicity, irritation, allergic response).
- pharmaceutically acceptable salts may be found in S. M. Berge, et al., J. Pharmaceutical Sciences, 66: 1-19 (1977), in which all information pertaining to the pharmaceutically acceptable salts and processes for preparation thereof are hereby incorporated by reference.
- salts can be prepared in situ during the final isolation and purification of the compounds taught herein or separately by reacting a free base or free acid moiety on the active pharmaceutical agent with a suitable reagent.
- Pharmaceutically acceptable salts include, acid salts, for example, mineral acid salts such as hydrochloride, sulfates salts, nitrate salts, phosphates salts, carbonates salts, hydrogencarbonates or perchlorate; organic acid salts such as acetates, propionates, lactates, maleates, fumarates, tararic acid salts, malates, citrates salts, ascorbates, formic acid; sulfonates such as methanesulfonates, isethionates, benzenesulfonates, or p-toluenesulfonates; and acidic amino acid salts such as aspartates or glutamates.
- mineral acid salts such as hydrochloride, sulfates salts, nitrate salts, phosphates salts, carbonates salts, hydrogencarbonates or perchlorate
- organic acid salts such as acetates, propionates, lactates, maleates, fuma
- the present invention provides a process for the preparation of lumacaftor that may include the steps of:
- X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described above.
- reaction of compound of formula II with formula III may be carried out in the presence of a catalyst, a ligand, base, and a suitable solvent.
- the base useful in this embodiment may be an organic base, an inorganic base, or mixtures thereof.
- Suitable organic bases useful for this reaction include, but are not limited to pyridine, trimethylamine, N, N-diisopropylethylamine, and mixturest thereof.
- Suitable inorganic bases for use in this reaction include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof.
- Suitable alkaline metal hydroxides for use in this reaction include, but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof.
- Suitable alkaline metal bicarbonates useful in this reaction include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof.
- Suitabel alkaline metal carbonates useful in this reaction include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof.
- Suitable alkaline alkoxides useful in this reaction include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof.
- cesium carbonate or sodium tert-butoxide as a base was found to be effective.
- the catalyst may be a palladium-containing catalyst.
- Suitable palladium-containing catalysts include, but are not limited to, bis(dibenzylideneacetone)palladium [Pd(dba)2] , tris(dibenzylideneacetone)dipalladium [Pd2(dba)3], palladium(II) acetate [Pd(OAc)2], [ 1 , 1 '-bis(diphenylphosphino) ferrocene]dichloropalladium(II)[Pd(dppf)C12], tetrakis (triphenylphosphine)palladium [Pd(PPh3)4], allylpalladium(II) chloride dimer [Pd(C3H5)Cl], and mixtures thereof.
- Pd(OAc)2 was found to be useful as a catalyst.
- Suitable ligands useful for this reaction include, but are not limited to, 4,5-bis(diphenylphosphino)-9,9- dimethylxanthene [xantphos], 2,2'-bis(diphenylphosphino)-l,l'-binaphthalene [BINAP], l,l '-bis(diphenyl phosphine) ferrocene [DPPF], 2-(diphenyl phosphine phenyl) ether [DPEphos], tri-t-butyl phosphine [Fu's salt], 2-dicyclohexylphosphino-2'-(N,N- dimethylamino)biphenyl [DavePhos], 2-di-tert-butylphosphino-2'-(N,N-dimethylamino) biphenyl [t-BuDavePhos], triphenylphosphine, trial
- the use of xantphos and BINAP as a ligand was found to be particularly effective.
- the solvent used may be a non-polar solvent, a polar aprotic solvent, a polar protic solvent, or mixtures thereof.
- Suitable non-polar solvents useful within this reaction include, but are not limited to, 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether (MTBE), dichloromethane, and mixtures thereof.
- Suitable polar aprotic solvents useful within this reaction include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N- dimethylformamide(DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane and mixtures thereof.
- Suitable polar protic solvents useful within this reaction include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, the use of 1,4-dioxane or toluene as a solvent was found to be particularly effective.
- this deprotection of formula la may be carried out as disclosed in PCT App. Pub. No. WO2009076142, which is hereby incorporated by reference for those process.
- deprotection of formula la may be carried out in presence of acid and a suitable solvent.
- the acid used in the deprotection step may be an organic acid or an inorganic acid.
- Suitable organic acids useful in this step include, but are not limited to, formic acid, acetic acid, propanoic acid, tartaric acid, oxalic acid, maleic acid, mandellic acid, malonic acid, methane sulphonic acid, p-toluene sulphonic acid, trifluoroacetic acid, benzene sulfonic acid, and combinations thereof.
- Suitable inorganic acids useful in this step include, but are not limited to, hydrochloric acid, hydrobromic acid, hydro iodic acid, sulphuric acid, nitric acid, boric acid, phosphoric acid, chromic acid, and combinations thereof. In some particularly useful embodiments, formic acid or hydrochloric acid is used as the acid.
- the solvent may be a polar aprotic solvent or a polar protic solvent.
- Suitable polar aprotic solvents include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N- dimethylformamide(DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane and mixtures thereof.
- Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, acetonitrile is used as the solvent.
- the present invention further provides a process for the preparation of lumacaftor that may include the steps of:
- X refers to any halogen and R is either hydrogen or a carboxylic acid protecting group, as described above.
- halogenation of the compound formula IV may be carried out in presence of halogenating agent, base, and suitable solvent.
- Suitable halogenating agents include, but are not limited to, phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl dibromide, oxalyl bromide, thionyl bromide, phosphorous bromide, phosphorus oxybromide, chloroacetyl chloride, methane sulfonyl chloride, benzene sulfonyl chloride, p-toluene sulfonyl chloride, and mixtures thereof.
- the specific identity of the halogenating agent will be impacted by the specific halogen that is being attached to the compound of Formula IV.
- phosphorus oxychloride is used as the halogenating agent.
- the base may be an organic base or an inorganic base.
- Suitable inorganic base useful in this step include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof.
- Suitable alkaline metal hydroxides useful in this step include, but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof.
- Suitable alkaline metal bicarbonates useful in this step include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof.
- Suitable alkaline metal carbonates useful in this step include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof.
- Suitable alkaline alkoxides useful in this step include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof.
- Suitable organic bases useful in this step include, but are not limited to, pyridine, triethylamine. N,N- diisopropylethylamine, tributyl amine, diisopropyl amine, and mixtures thereof. In some particularly useful embodiments, trimethylamine is used as the base.
- the solvent may be a non-polar solvent, a polar aprotic solvent, a polar protic solvent, or mixtures thereof.
- Suitable non-polar solvents for this step include, but are not limited to, 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether (MTBE), dichloromethane, and mixtures thereof.
- Suitable polar aprotic solvents useful in this step include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N-dimethylformamide(DMF), N,N- dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane, and mixtures thereof.
- Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, dichloromethane is used as the solvent.
- coupling the compound of formula V with a compound of formula VI may be carried out in presence of a base, catalyst, and a suitable solvent to get compound formula la.
- the base may be an organic base or an inorganic base.
- Suitable inorganic base useful in this step include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof.
- Suitable alkaline metal hydroxides useful in this step include, but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof.
- Suitable alkaline metal bicarbonates useful in this step include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof.
- Suitable alkaline metal carbonates useful in this step include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof.
- Suitable alkaline alkoxides useful in this step include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof.
- Suitable organic bases useful in this step include, but are not limited to, pyridine, triethylamine. N,N- diisopropylethylamine, tributyl amine, diisopropyl amine, and mixtures thereof. In some particularly useful embodiments, the base is potassium bicarbonate or sodium bicarbonate.
- Suitable catalysts useful for this step include, but are not limited to, Pd(dba) 2 , Pd 2 (dba) 3j Pd(OAc) 2, Pd(dppf)Cl 2 , Pd(PPh 3 ) 4 , copper, cuprous bromide, cuprous iodide, 2,2'-bis- diphenylphosphanyl[l, l'] binaphtalenyl (rac-Binap), [Pd(C 3 H5)Cl] 2 , and mixtures thereof.
- Pd(dppf)Cl 2 is used as a catalyst.
- the solvent may be a polar aprotic solvent or a polar protic solvent.
- Suitable polar aprotic solvents useful in this step include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N-dimethylformamide (DMF), ⁇ , ⁇ -dimethylacetamide (DMA), N- methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane, and mixtures thereof.
- Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, N,N-dimethylformamide is used as a solvent.
- the present invention further provides a process for the preparation of a compound of formula II as shown in the following scheme.
- X refers to any halogen.
- This embodiment thus provides a process for the preparation intermediate of a compound of formula II that may include the step of converting the compound of formula lib to compound of formula II.
- conversion of the compound of formula lib to the compound of formula II may be carried out in the presence of an ammonia source and a suitable solvent.
- suitable ammonia sources useful in the step include, but are not limited to, ammonium hydroxide, ammonia gas, ammonium acetate, ammonium formate, and mixtures thereof.
- the ammonia source is ammonium hydroxide.
- the solvent may be a non-polar solvent.
- suitable non-polar solvents useful in this step include, but are not limited to 1,4- dioxane, toluene, benzene, xylene, methyl t-butyl ether, dichloromethane, and mixtures thereof.
- the solvent is toluene.
- the present invention also provides processes for the preparation of a compound of formula II as shown in the following scheme.
- Formula Ila Formula lib Formula II within the context of this embodiment, X may be any halogen.
- This embodiment thus provides an in situ process for the preparation of an intermediate of the compound of formula II that may include the steps of: a) halogenating a compound of formula Ila with halogenating agent to get a compound of formula lib; and b) converting the compound of formula lib to a compound of formula II.
- halogenation of formula Ila may be carried out as disclosed in U.S. Patent App. Pub. No. 20080306062 and PCT App. Pub. No. WO2009076142, both of which are incorporated by reference with respect to those processes.
- halogenation may occur in the presence of a halogenating agent and a suitable solvent.
- Suitable halogenating agents useful for this step include, but are not limited to, phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl dibromide, oxalyl bromide, thionyl bromide, phosphorous bromide and phosphorus oxybromide chloroacetyl chloride, methane sulfonyl chloride, benzene sulfonyl chloride, p-toluene sulfonyl chloride, and mixtures thereof.
- thionyl chloride was found to be effective as a halogenating agent.
- the solvent used in this embodiment may be a polar aprotic solvents or a polar protic solvent.
- Suitable polar aprotic solvents useful within this reaction include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, acetone, N,N-dimethylformamide(DMF), N,N-dimethylacetamide (DMA), N- methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane, and mixtures thereof.
- MEK methyl ethyl ketone
- NMP N-methylpyrrolidinone
- DMSO dimethylsulfoxide
- Suitable polar protic solvents useful within this reaction include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof.
- N,N-dimethylformamide was found to be effective as a solvent.
- conversion compound of formula lib to compound of formula II may be carried out in presence of an ammonia source and a suitable solvent.
- Suitable ammonia sources useful in this step include, but are not limited to, ammonium hydroxide, ammonia gas, ammonium acetate, ammonium formate, and mixtures thereof. In some particularly useful embodiments, ammonium hydroxide was found to be effective as an ammonia source.
- the solvent useful in this step may be a non-polar solvent.
- Suitable non-polar solvents useful in this step include, but are not limited to 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether, dichloromethane, and mixtures thereof. In some particularly useful embodiments, toluene was found to be effective as the solvent.
- This embodiment provides a process of hydrolysis of cyano compound of formula lid which may be carried out in presence an acid and a base. Additionally, peroxides (e.g., hydrogen peroxide) may optionally be utilized to get to compound of formula II.
- the acid used in this reaction may be an organic acid or an inorganic acid. Suitable organic acids useful in this step include, but are not limited to, formic acid, acetic acid, propanoic acid, methane sulphonic acid, p-toluene sulphonic acid, trifluoroacetic acid, and mixtures thereof.
- Suitable inorganic acids useful in this step include, but are not limited to, hydrochloric acid, hydrobromic acid, hydro iodic acid, sulphuric acid, nitric acid, and combinations thereof. In some particularly useful embodiments, trifluoroacetic acid, sulphuric acid, and mixtures thereof were used as the acid.
- the base used in this reaction may be an organic base or an inorganic base.
- Suitable inorganic bases useful in this reaction include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof.
- Suitable alkaline metal hydroxides useful in this reaction include, but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof.
- Suitable alkaline metal bicarbonates useful in this reaction include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof.
- Suitable alkaline metal carbonates useful in this reaction include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof.
- Suitable alkaline alkoxides useful in this reaction include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert- butoxide, potassium tert-butoxide, and mixtures thereof.
- Suitable organic bases useful in this reaction include, but are not limited to, pyridine, triethylamine and N, N- diisopropylethylamine, tributyl amine, diisopropyl amine, and mixtures thereof. In some particularly useful embodiments, potassium carbonate was used as the base..
- the solvent may be a polar aprotic solvent or a polar protic solvent.
- Suitable polar aprotic solvents for this reaction include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N-dimethylformamide(DMF), ⁇ , ⁇ -dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane and mixtures thereof.
- Suitable polar protic solvents useful in this reaction include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, DMSO was utilized as the solvent.
- an additional in situ process for the preparation of a compound of formula II as depicted in scheme may include the steps of: a) reacting a compound of formula lie with a compound of formula He to get a compound of formula lid; and b) converting the compound of formula lid to compound of formula II.
- LG represents leaving group, as described above.
- a compound of formula lie is reacted with a compound of formula He to get a compound of formula lid.
- This process may be carried out as disclosed in U.S. Patent App. Pub. No. 20080306062 and PCT App. Pub. No. WO2009076142, both of which are hereby incorporated by reference with respect to those processes.
- present invention provides a process for the preparation of a compound of formula III as shown in scheme.
- this embodiment provides processes for the preparation of a compound of formula III, comprising, halogenating the compound of formula Hid with halogenating agent to get the compound of formula III.
- halogenation a compound of formula Hid may be carried out in presence of a halogenating agent, a base, and a solvent.
- Suitable halogenating agents for this reaction include, but are not limited to, phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl dibromide, oxalyl bromide, thionyl bromide, phosphorous bromide, phosphorus oxybromide, chloroacetyl chloride, methane sulfonyl chloride, benzene sulfonyl chloride, p-toluene sulfonyl chloride, and mixtures thereof.
- phosphorus oxychloride is used as a halogenating agent.
- the base may be an organic base or an inorganic base.
- Suitable inorganic bases for this reaction include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof.
- Suitable alkaline metal hydroxides useful in this reaction include, but are not limited to sodium hydroxide, potassium hydroxide, and mixtures thereof.
- Suitable alkaline metal bicarbonates useful for this reaction include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof.
- Suitable alkaline metal carbonates useful for this reaction include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof.
- Suitable alkaline alkoxides useful in this step include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof.
- Suitable organic bases useful for this reaction include, but are not limted to pyridine, trimethylamine, N,N- diisopropylethylamine, and mixtures thereof
- the solvent may be a non-polar solvent.
- Suitable non-polar solvents for this reaction include, but are not limited to 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether (MTBE), dichloromethane, and mixtures thereof. In some particularly useful embodiments, dichloromethane was used as the solvent.
- the present invention provides process for the preparation of a compound of formula III as shown in scheme.
- Formula Ilia Formula Illb Formula IIIc Formula Hid Formula III
- X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described above.
- This embodiment provides a process for the preparation of a compound of formula III, comprising the steps of: a) coupling the compounds of formula Ilia and Illb to get a compound of formula IIIc;
- coupling the compounds of formula Ilia and Illb may be carried out in the presence base and catalyst to get a compound of formula IIIc, followed by oxidizing the compound of formula IIIc with a suitable oxidizing agent to get a compound of formula Hid as disclosed in the PCT App. Pub. No. WO2009076142, which is hereby incorporated by reference for those processes.
- aqueous ammonia solution (40 mL) was slowly added at 10-15 °C and maintained for 2 hours at 25-30 °C. After completion of reaction, 20 ml of water was added to the reaction mixture, and the reaction mixture was then stirred for 15 min. The layers were separated, the aqueous layer was extracted with 40 ml toluene. The combined toluene layer was washed with water. The remaining solvent was completely removed under vacuum at 50-55 °C. The resulting residue was triturated with acetone and hexane mixture (10 mL) for 1 hour. The obtained solid was filtered and washed with hexane (5 ml).
- the combined ethyl acetate layer was washed with water.
- the solvent was completely removed under vacuum at 50-55 °C.
- 50 ml dimethyl sulfoxide, 1.12 g potassium carbonate and 8.7 g 30% hydrogen peroxide were added at 15-20 °C.
- the reaction mixture was heated to 25- 30 °C and maintained for 3 hours.
- 100 ml water, 100 ml toluene were added to the reaction mixture.
- the layers were seapareted, and the aqueous layer was extracted with 50 ml toluene.
- the toluene layer was washed with 50ml 10% sodium sulfite, followed by washing with 50 ml water.
- reaction mass was filtered through Hyflo and washed with 10 ml 1,4-dioxane. Filtrate was isolated completely under vacuum. 100 ml toluene was then added and the reaction mass was stirred for 10 min. The reaction mass was washed with 20 ml of water. Toluene was distilled out completely under vacuum to afford 16 g of crude 3-(6-(l-(2,2- difluorobenzo[d] [ 1 ,3]dioxol-5-yl)cyclopropane carboxamido) -3-methylpyridin-2-yl)-t- butylbenzoate ( 95.8% yield).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present disclosure relates to processes for the preparation of lumacaftor useful for treating a cystic fibrosis transmembrane conductance regulator (CFTR)-mediated disease such as cystic fibrosis. The present disclosure also provides intermediates useful in the preparation of lumacaftor
Description
PROCESS FOR THE PREPARATION OF LUMACAFTOR
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of Indian provisional patent application No. 3831 /CHE/2015 filed on July 27, 2015, which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
The present invention relates to novel process for the preparation of lumacaftor useful for treating a cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease such as cystic fibrosis.
BACKGROUND OF THE INVENTION
Lumacaftor, 3-(6-( 1 -(2,2-difluorobenzo[d] [ 1 ,3]dioxol-5-yl)cyclopropanecarboxamido)-3- methylpyridin-2-yl)benzoic acid having the following structure (Formula I), is useful for treating or lessening the severity of a variety of cystic fibrosis transmembrane conductance regul
Formula I U.S. Patent App. Pub. No. 20130245010, which is hereby incorporated by reference, discloses lumacaftor compound and process for the preparation of the same.
Further PCT App. Pub. No. WO2009076142, which is hereby incorporated by reference, discloses processes for the preparation of lumacaftor or its intermediates. Lumacaftor and its salt polymoprhs are disclosed in PCT App. Pub. Nos. WO2009073757 and WO2011127290, which are hereby incorporated by reference.
The present invention relates to a process for the preparation of lumacaftor and its pharmaceutically acceptable salts.
SUMMARY OF THE INVENTION
The present invention provides processes for the preparation of lumacaftor and its pharmaceutically acceptable salts.
In one aspect, the present invention provides a process for the preparation of lumacaftor, that may include the steps of:
a) reacting a compound of formula II with a compound of formula III to get formula la;
Formula la
b) optionally deprotecting the compound of formula la to get lumacaftor.
Within the context of this scheme, X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described below.
Another aspect of the present invention encompasses processes for the preparation of lumacaftor that may include the steps of:
a) halogenating the compound of formula IV with halogenating agent to produce compound of formula V;
Formula IV Formula V b) coupling the compound of formula V with a compound of formula VI to get a compound of formula la; and
Formula la
c) optionally deprotecting the compound of formula la to give Lumacaftor (formula I).
Within the context of this scheme, X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described below.
In another aspect, the present invention provides a process for the preparation of a compound of formula II as shown in scheme.
Formula II
Formula lib
Within this context, the present invention provides a process for the preparation of formula II that may include the step of converting a compound of formula lib to compound of formula II, where X is any halogen.
In another aspect, the present invention provides additional processes for the preparation of a com ound of formula II as shown in scheme.
Formula lid Formula II
10
Within this context, the present invention provides a process for the preparation of a compound of formula II that may include the step of converting compound of formula lid to compound of formula II.
In another aspect, the present invention provides a process for the preparation of a compound of formula III as shown in scheme.
Formula 11 Id Formula III
Within this context, the present invention provides a process for the preparation of a compound of formula III that may include the steps of halogenating the compound of formula Hid with halogenating agent to get a compound of formula III. Within the context of this scheme, X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described below.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to process for the preparation of CFTR corrector lumacaftor or its pharmaceutically acceptable salts.
As used herein, examples of suitable "leaving groups" (LG) include, but are not limited to halogens (e.g., fluorine, chlorine, bromine, iodine), methanesulfonyloxy, p- toluenesulfonyloxy, trifluoromethanesulfonyloxy, nonafluorobutanesulfonyloxy, (4- bromo-benzene)sulfonyloxy, (4-nitro-benzene)sulfonyloxy, (2-nitro-benzene)- sulfonyloxy, (4-isopropyl-benzene)sulfonyloxy, (2,4,6-tri-isopropyl-benzene)- sulfonyloxy, (2,4,6-trimethyl-benzene)sulfonyloxy, (4-tertbutyl-benzene)sulfonyloxy, benzenesulfonyloxy, (4-methoxy-benzene)sulfonyloxy, and alkoxy. The term "alkoxy," as used herein, refers to straight chain or branched chain alkyl groups containing 1 to 6 carbons.
Suitable alkoxy groups useful within the context of the present invention include, but are not limited to, methoxy, ethoxy, propoxy, 1 -methylethoxy, butoxy, 1 , 1 -dimethyl ethoxy, and 1-methylpropoxy. An alkoxy group may be substituted by one or more halogens, or may be unsubstituted. In certain embodiments, methoxy, ethoxy, and trifluoromethoxy were found to be particularly effective as leaving groups.
As used herein "X" means any halogen. Suitable halogens useful within the context of the present invention include, but are not limited to, fluorine, chlorine, bromine, and iodine.
As used herein, the term "carboxylic acid protecting group" means a chemical moiety that protects a carboxylic acid residue from unwanted reaction. Suitable carboxylic acid protecting groups useful with in the context of the present invention include, but are not limited to, alkyl ester such as methyl ester, ethyl ester, t-butyl ester; arakyl ester such as benzyl ester ; silyl ester, and oxazoline.
The phrase "pharmaceutically acceptable salt" is well known and understood in the art and refers to salts of pharmaceutically active agents which are suitable for use in contact with the tissues of humans and lower animals without undue adverse effects (e.g.,
toxicity, irritation, allergic response). Examples of pharmaceutically acceptable salts may be found in S. M. Berge, et al., J. Pharmaceutical Sciences, 66: 1-19 (1977), in which all information pertaining to the pharmaceutically acceptable salts and processes for preparation thereof are hereby incorporated by reference.
Methods for the preparation of a pharmaceutically acceptable salt of an active pharmaceutical agent is well known in the art. For example, the salts can be prepared in situ during the final isolation and purification of the compounds taught herein or separately by reacting a free base or free acid moiety on the active pharmaceutical agent with a suitable reagent. Pharmaceutically acceptable salts include, acid salts, for example, mineral acid salts such as hydrochloride, sulfates salts, nitrate salts, phosphates salts, carbonates salts, hydrogencarbonates or perchlorate; organic acid salts such as acetates, propionates, lactates, maleates, fumarates, tararic acid salts, malates, citrates salts, ascorbates, formic acid; sulfonates such as methanesulfonates, isethionates, benzenesulfonates, or p-toluenesulfonates; and acidic amino acid salts such as aspartates or glutamates.
In some embodiments, the present invention provides a process for the preparation of lumacaftor that may include the steps of:
a) reacting a compound of formula II with a compound of formula III to get formula la; and
Formula la
b) optionally deprotecting the compound of formula la to get lumacaftor.
As used in this scheme, X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described above. In these embodiments of the present invention, reaction of compound of formula II with formula III may be carried out in the presence of a catalyst, a ligand, base, and a suitable solvent.
The base useful in this embodiment may be an organic base, an inorganic base, or mixtures thereof. Suitable organic bases useful for this reaction include, but are not limited to pyridine, trimethylamine, N, N-diisopropylethylamine, and mixturest thereof. Suitable inorganic bases for use in this reaction include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof. Suitable alkaline metal hydroxides for use in this reaction include, but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof. Suitable alkaline metal bicarbonates useful in this reaction include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof. Suitabel alkaline metal carbonates useful in this reaction include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof. Suitable alkaline alkoxides useful in this reaction include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium
propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof. In some particularly useful embodiments, the use of cesium carbonate or sodium tert-butoxide as a base was found to be effective.
Within the context of this embodiment, the catalyst may be a palladium-containing catalyst. Suitable palladium-containing catalysts include, but are not limited to, bis(dibenzylideneacetone)palladium [Pd(dba)2] , tris(dibenzylideneacetone)dipalladium [Pd2(dba)3], palladium(II) acetate [Pd(OAc)2], [ 1 , 1 '-bis(diphenylphosphino) ferrocene]dichloropalladium(II)[Pd(dppf)C12], tetrakis (triphenylphosphine)palladium [Pd(PPh3)4], allylpalladium(II) chloride dimer [Pd(C3H5)Cl], and mixtures thereof. In some particularly effective embodiments, Pd(OAc)2 was found to be useful as a catalyst.
Within the context of this embodiment, the ligand does what? Suitable ligands useful for this reaction include, but are not limited to, 4,5-bis(diphenylphosphino)-9,9- dimethylxanthene [xantphos], 2,2'-bis(diphenylphosphino)-l,l'-binaphthalene [BINAP], l,l '-bis(diphenyl phosphine) ferrocene [DPPF], 2-(diphenyl phosphine phenyl) ether [DPEphos], tri-t-butyl phosphine [Fu's salt], 2-dicyclohexylphosphino-2'-(N,N- dimethylamino)biphenyl [DavePhos], 2-di-tert-butylphosphino-2'-(N,N-dimethylamino) biphenyl [t-BuDavePhos], triphenylphosphine, trialkyl phosphines, and mixtures thereof. In some particularly useful embodiments, the use of xantphos and BINAP as a ligand was found to be particularly effective. Within the context of this embodiment, the solvent used may be a non-polar solvent, a polar aprotic solvent, a polar protic solvent, or mixtures thereof. Suitable non-polar solvents useful within this reaction include, but are not limited to, 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether (MTBE), dichloromethane, and mixtures thereof. Suitable polar aprotic solvents useful within this reaction include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N- dimethylformamide(DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane and mixtures thereof. Suitable polar protic solvents useful within this reaction include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some
particularly useful embodiments, the use of 1,4-dioxane or toluene as a solvent was found to be particularly effective.
Within the context of this embodiment, this deprotection of formula la may be carried out as disclosed in PCT App. Pub. No. WO2009076142, which is hereby incorporated by reference for those process. For example, deprotection of formula la may be carried out in presence of acid and a suitable solvent. The acid used in the deprotection step may be an organic acid or an inorganic acid. Suitable organic acids useful in this step include, but are not limited to, formic acid, acetic acid, propanoic acid, tartaric acid, oxalic acid, maleic acid, mandellic acid, malonic acid, methane sulphonic acid, p-toluene sulphonic acid, trifluoroacetic acid, benzene sulfonic acid, and combinations thereof. Suitable inorganic acids useful in this step include, but are not limited to, hydrochloric acid, hydrobromic acid, hydro iodic acid, sulphuric acid, nitric acid, boric acid, phosphoric acid, chromic acid, and combinations thereof. In some particularly useful embodiments, formic acid or hydrochloric acid is used as the acid. Within the context of this embodiment, the solvent may be a polar aprotic solvent or a polar protic solvent. Suitable polar aprotic solvents include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N- dimethylformamide(DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane and mixtures thereof. Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, acetonitrile is used as the solvent.
The present invention further provides a process for the preparation of lumacaftor that may include the steps of:
a) halogenating the compound of formula IV with a halogenating agent to produce compound of formula V;
Formula IV Formula V b) coupling the compound of formula V with a compound of formula VI to get compound formula la;
Δ Formula VI
Formula I
In these structures, X refers to any halogen and R is either hydrogen or a carboxylic acid protecting group, as described above. In this embodiment, halogenation of the compound formula IV may be carried out in presence of halogenating agent, base, and suitable solvent. Suitable halogenating agents include, but are not limited to, phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl dibromide, oxalyl bromide, thionyl bromide,
phosphorous bromide, phosphorus oxybromide, chloroacetyl chloride, methane sulfonyl chloride, benzene sulfonyl chloride, p-toluene sulfonyl chloride, and mixtures thereof. The specific identity of the halogenating agent will be impacted by the specific halogen that is being attached to the compound of Formula IV. In some particularly useful embodiments, phosphorus oxychloride is used as the halogenating agent.
Within the context of this embodiment, the base may be an organic base or an inorganic base. Suitable inorganic base useful in this step include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof. Suitable alkaline metal hydroxides useful in this step include, but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof. Suitable alkaline metal bicarbonates useful in this step include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof. Suitable alkaline metal carbonates useful in this step include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof. Suitable alkaline alkoxides useful in this step include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof. Suitable organic bases useful in this step include, but are not limited to, pyridine, triethylamine. N,N- diisopropylethylamine, tributyl amine, diisopropyl amine, and mixtures thereof. In some particularly useful embodiments, trimethylamine is used as the base.
Within the context of this embodiment, the solvent may be a non-polar solvent, a polar aprotic solvent, a polar protic solvent, or mixtures thereof. Suitable non-polar solvents for this step include, but are not limited to, 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether (MTBE), dichloromethane, and mixtures thereof. Suitable polar aprotic solvents useful in this step include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N-dimethylformamide(DMF), N,N- dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane, and mixtures thereof. Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures
thereof. In some particularly useful embodiments, dichloromethane is used as the solvent.
Within the context of this embodiment, coupling the compound of formula V with a compound of formula VI may be carried out in presence of a base, catalyst, and a suitable solvent to get compound formula la. The base may be an organic base or an inorganic base. Suitable inorganic base useful in this step include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof. Suitable alkaline metal hydroxides useful in this step include, but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof. Suitable alkaline metal bicarbonates useful in this step include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof. Suitable alkaline metal carbonates useful in this step include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof. Suitable alkaline alkoxides useful in this step include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof. Suitable organic bases useful in this step include, but are not limited to, pyridine, triethylamine. N,N- diisopropylethylamine, tributyl amine, diisopropyl amine, and mixtures thereof. In some particularly useful embodiments, the base is potassium bicarbonate or sodium bicarbonate.
Suitable catalysts useful for this step include, but are not limited to, Pd(dba)2, Pd2(dba)3j Pd(OAc)2, Pd(dppf)Cl2, Pd(PPh3)4, copper, cuprous bromide, cuprous iodide, 2,2'-bis- diphenylphosphanyl[l, l'] binaphtalenyl (rac-Binap), [Pd(C3H5)Cl]2, and mixtures thereof. In some particularly useful embodiments Pd(dppf)Cl2 is used as a catalyst. Within the context of this embodiment, the solvent may be a polar aprotic solvent or a polar protic solvent. Suitable polar aprotic solvents useful in this step include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N-dimethylformamide (DMF), Ν,Ν-dimethylacetamide (DMA), N- methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane, and
mixtures thereof. Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, N,N-dimethylformamide is used as a solvent.
The present invention further provides a process for the preparation of a compound of formula II as shown in the following scheme.
Formula II
Formula lib
Within the context of this reaction, X refers to any halogen. This embodiment thus provides a process for the preparation intermediate of a compound of formula II that may include the step of converting the compound of formula lib to compound of formula II. Within the context of this embodiment, conversion of the compound of formula lib to the compound of formula II may be carried out in the presence of an ammonia source and a suitable solvent. Examples of suitable ammonia sources useful in the step include, but are not limited to, ammonium hydroxide, ammonia gas, ammonium acetate, ammonium formate, and mixtures thereof. In some particularly useful embodiments, the ammonia source is ammonium hydroxide.
Within the context of this embodiment, the solvent may be a non-polar solvent. Examples of suitable non-polar solvents useful in this step include, but are not limited to 1,4- dioxane, toluene, benzene, xylene, methyl t-butyl ether, dichloromethane, and mixtures thereof. In some particularly useful embodiments, the solvent is toluene. The present invention also provides processes for the preparation of a compound of formula II as shown in the following scheme.
Formula Ila Formula lib Formula II
Within the context of this embodiment, X may be any halogen. This embodiment thus provides an in situ process for the preparation of an intermediate of the compound of formula II that may include the steps of: a) halogenating a compound of formula Ila with halogenating agent to get a compound of formula lib; and b) converting the compound of formula lib to a compound of formula II.
Within the context of this embodiment, halogenation of formula Ila may be carried out as disclosed in U.S. Patent App. Pub. No. 20080306062 and PCT App. Pub. No. WO2009076142, both of which are incorporated by reference with respect to those processes. For example, halogenation may occur in the presence of a halogenating agent and a suitable solvent. Suitable halogenating agents useful for this step include, but are not limited to, phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl dibromide, oxalyl bromide, thionyl bromide, phosphorous bromide and phosphorus oxybromide chloroacetyl chloride, methane sulfonyl chloride, benzene sulfonyl chloride, p-toluene sulfonyl chloride, and mixtures thereof. In some particularly useful embodiments, thionyl chloride was found to be effective as a halogenating agent.
The solvent used in this embodiment may be a polar aprotic solvents or a polar protic solvent. Suitable polar aprotic solvents useful within this reaction include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, acetone, N,N-dimethylformamide(DMF), N,N-dimethylacetamide (DMA), N- methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane, and mixtures thereof. Suitable polar protic solvents useful within this reaction include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, N,N-dimethylformamide was found to be effective as a solvent.
In the second step of the reaction of this embodiment, conversion compound of formula lib to compound of formula II may be carried out in presence of an ammonia source and
a suitable solvent. Suitable ammonia sources useful in this step include, but are not limited to, ammonium hydroxide, ammonia gas, ammonium acetate, ammonium formate, and mixtures thereof. In some particularly useful embodiments, ammonium hydroxide was found to be effective as an ammonia source. The solvent useful in this step may be a non-polar solvent. Suitable non-polar solvents useful in this step include, but are not limited to 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether, dichloromethane, and mixtures thereof. In some particularly useful embodiments, toluene was found to be effective as the solvent.
In another embodiment of the present invention, an additional process for the preparation of a compound of formula II is disclosed and is shown in scheme.
Formula lid Formula II
This embodiment provides a process of hydrolysis of cyano compound of formula lid which may be carried out in presence an acid and a base. Additionally, peroxides (e.g., hydrogen peroxide) may optionally be utilized to get to compound of formula II. The acid used in this reaction may be an organic acid or an inorganic acid. Suitable organic acids useful in this step include, but are not limited to, formic acid, acetic acid, propanoic acid, methane sulphonic acid, p-toluene sulphonic acid, trifluoroacetic acid, and mixtures thereof. Suitable inorganic acids useful in this step include, but are not limited to, hydrochloric acid, hydrobromic acid, hydro iodic acid, sulphuric acid, nitric acid, and combinations thereof. In some particularly useful embodiments, trifluoroacetic acid, sulphuric acid, and mixtures thereof were used as the acid.
The base used in this reaction may be an organic base or an inorganic base. Suitable inorganic bases useful in this reaction include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof. Suitable alkaline metal hydroxides useful in this reaction include,
but are not limited to, sodium hydroxide, potassium hydroxide, and mixtures thereof. Suitable alkaline metal bicarbonates useful in this reaction include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof. Suitable alkaline metal carbonates useful in this reaction include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof. Suitable alkaline alkoxides useful in this reaction include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert- butoxide, potassium tert-butoxide, and mixtures thereof. Suitable organic bases useful in this reaction include, but are not limited to, pyridine, triethylamine and N, N- diisopropylethylamine, tributyl amine, diisopropyl amine, and mixtures thereof. In some particularly useful embodiments, potassium carbonate was used as the base..
Within the context of this embodiment, the solvent may be a polar aprotic solvent or a polar protic solvent. Suitable polar aprotic solvents for this reaction include, but are not limited to, acetone, acetonitrile, methyl ethyl ketone (MEK), methyl isobutyl ketone, N,N-dimethylformamide(DMF), Ν,Ν-dimethylacetamide (DMA), N-methylpyrrolidinone (NMP), dimethylsulfoxide (DMSO), 1 ,2-dimethoxyethane and mixtures thereof. Suitable polar protic solvents useful in this reaction include, but are not limited to, water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof. In some particularly useful embodiments, DMSO was utilized as the solvent. In another embodiment of the present invention, there is disclosed an additional in situ process for the preparation of a compound of formula II as depicted in scheme that may include the steps of: a) reacting a compound of formula lie with a compound of formula He to get a compound of formula lid; and b) converting the compound of formula lid to compound of formula II.
Formula lie Formula I Id Formula II
Within this reaction scheme, LG represents leaving group, as described above. Within the context of this embodiment, a compound of formula lie is reacted with a compound of formula He to get a compound of formula lid. This process may be carried out as disclosed in U.S. Patent App. Pub. No. 20080306062 and PCT App. Pub. No. WO2009076142, both of which are hereby incorporated by reference with respect to those processes.
In another embodiment, present invention provides a process for the preparation of a compound of formula III as shown in scheme.
Formula Hid Formula III
Accordingly, this embodiment provides processes for the preparation of a compound of formula III, comprising, halogenating the compound of formula Hid with halogenating agent to get the compound of formula III. In this embodiment, halogenation a compound of formula Hid may be carried out in presence of a halogenating agent, a base, and a solvent.
Suitable halogenating agents for this reaction include, but are not limited to, phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl dibromide, oxalyl bromide, thionyl bromide, phosphorous bromide, phosphorus oxybromide, chloroacetyl chloride, methane sulfonyl chloride, benzene sulfonyl chloride, p-toluene sulfonyl chloride, and mixtures thereof. In
some particularly effective embodiments, phosphorus oxychloride is used as a halogenating agent.
Within the context of this reaction, the base may be an organic base or an inorganic base. Suitable inorganic bases for this reaction include, but are not limited to, alkaline metal hydroxides, alkaline metal bicarbonates, alkaline metal carbonates, alkaline alkoxides, and mixtures thereof. Suitable alkaline metal hydroxides useful in this reaction include, but are not limited to sodium hydroxide, potassium hydroxide, and mixtures thereof. Suitable alkaline metal bicarbonates useful for this reaction include, but are not limited to, sodium bicarbonate, potassium bicarbonate, and mixtures thereof. Suitable alkaline metal carbonates useful for this reaction include, but are not limited to, sodium carbonate, potassium carbonate, cesium carbonate, and mixtures thereof. Suitable alkaline alkoxides useful in this step include, but are not limited to, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof. Suitable organic bases useful for this reaction include, but are not limted to pyridine, trimethylamine, N,N- diisopropylethylamine, and mixtures thereof
For this reaction, the solvent may be a non-polar solvent. Suitable non-polar solvents for this reaction include, but are not limited to 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether (MTBE), dichloromethane, and mixtures thereof. In some particularly useful embodiments, dichloromethane was used as the solvent.
In a further embodiment, the present invention provides process for the preparation of a compound of formula III as shown in scheme.
Formula Ilia Formula Illb Formula IIIc Formula Hid Formula III
Within the context of this scheme X is any halogen and R is either hydrogen or a carboxylic acid protecting group, as described above. This embodiment provides a process for the preparation of a compound of formula III, comprising the steps of: a) coupling the compounds of formula Ilia and Illb to get a compound of formula IIIc;
b) oxidizing the compound of formula IIIc to get a compound of formula Hid; and c) halogenating the compound of formula Hid with a halogenating agent to get a compound of formula III.
Within the context of this embodiment, coupling the compounds of formula Ilia and Illb may be carried out in the presence base and catalyst to get a compound of formula IIIc, followed by oxidizing the compound of formula IIIc with a suitable oxidizing agent to get a compound of formula Hid as disclosed in the PCT App. Pub. No. WO2009076142, which is hereby incorporated by reference for those processes.
The following examples are provided to illustrate the process of the present invention. They, are however, not intended to limit the scope of the present invention in any way. Several variants of these examples would be evident to person ordinarily skilled in the art.
Example 1:
Preparation of l-(2-2-difluoro-benzo[l,3]dioxol-5-yl)-cyclopropanecarboxylic acid amide
A mixture of 10 g of l-(2-2-difluoro-benzo[l,3]dioxol-5-yl)-cyclopropanecarboxylic acid 50 ml toluene, and 0.1 ml dimethylformamide (DMF) was stirred for 15 min. To the reaction mixture was added 6.4 g of thionyl chloride, then the reaction mixture was heated to 60-65 °C and maintained for 2-3 hours. After completion of reaction, the solvent was completely distilled off under vacuum. Toluene (15 ml) was added and distilled out completely under vacuum. To the residue, 25 ml toluene was added at room temperature. To the reaction mass, aqueous ammonia solution (40 mL) was slowly added at 10-15 °C and maintained for 2 hours at 25-30 °C. After completion of reaction, 20 ml of water was added to the reaction mixture, and the reaction mixture was then stirred for
15 min. The layers were separated, the aqueous layer was extracted with 40 ml toluene. The combined toluene layer was washed with water. The remaining solvent was completely removed under vacuum at 50-55 °C. The resulting residue was triturated with acetone and hexane mixture (10 mL) for 1 hour. The obtained solid was filtered and washed with hexane (5 ml). The wet material was dried under vacuum to afford l-(2-2- difluoro-benzo[l,3]dioxol-5-yl)-cyclopropanecarboxylic acid amide (6.0 g , 60.3 % yield).
Example 2:
Preparation of l-(2-2-difluoro-benzo[l,3]dioxol-5-yl)-cyclopropane carboxylic acid amide
A mixture of 10 g of (2-2-difluoro-benzo[l,3]dioxol-5-yl)-acetonitrile, 10 g benzyltriethylammonium chloride, and 14.8 g 1 -bromo-2-chloro ethane was stirred for 15 min. To the reaction mixture was added 30 ml 50% sodium hydroxide solution at room temperature, then the reaction mixture was heated to 70-75°C and maintained for 15 hours. After completion of reaction, 100 ml ethyl acetate and 100 ml water were added at room temperature and the reaction mixture was stirred for 15 min. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined ethyl acetate layer was washed with water. The solvent was completely removed under vacuum at 50-55 °C. To the resulted residue, 50 ml trifluoroacetic acid (TFA) and 12.5 ml sulfuric acid were added slowly at room temperature, then the mixture was heated at reflux for 4-5 hours. After completion of reaction, 100 ml of ice-cold water was added to the reaction mixture. The reaction mixture was then separated, and the aqueous layer was extracted with toluene. The toluene layer was washed with water. The solvent was completely removed under vacuum at 50-55 °C. The resulting residue was triturated with acetone and hexane mixture (10 mL) for 1 hour. The solid obtained was filtered and washed with hexane (5 ml). The wet material was dried under vacuum to afford l-(2-2- difluoro-benzo[l,3]dioxol-5-yl)-cyclopropanecarboxylic acid amide (6.0 g , 49 % yield)
Example 3:
Preparation of l-(2-2-difluoro-benzo[l,3]dioxol-5-yl)-cyclopropane carboxylic acid amide
A mixture of 10 g of (2-2-difluoro-benzo[l,3]dioxol-5-yl)-acetonitrile, 10 g benzyltriethylammonium chloride, and 14.8 g 1 -bromo-2-chloro ethane was stirred for 15 min. To the reaction mixture was added 30 ml 50% sodium hydroxide solution at room temperature, then the reaction mixture was heated to 70-75 °C and maintained for 15 hours. After completion of reaction, 100 ml ethyl acetate and 100 ml water were added at room temperature and stirred for 15 min. The layers were separated, and the aqueous layer was extracted with 25 ml ethyl acetate. The combined ethyl acetate layer was washed with water. The solvent was completely removed under vacuum at 50-55 °C. To the resulting residue, 50 ml dimethyl sulfoxide, 1.12 g potassium carbonate and 8.7 g 30% hydrogen peroxide were added at 15-20 °C. The reaction mixture was heated to 25- 30 °C and maintained for 3 hours. After completion of reaction, 100 ml water, 100 ml toluene were added to the reaction mixture. The layers were seapareted, and the aqueous layer was extracted with 50 ml toluene. The toluene layer was washed with 50ml 10% sodium sulfite, followed by washing with 50 ml water. The solvent was completely removed under vacuum at 50-55 °C. The resulting residue was triturated with hexanes (50 mL) for 1 hour. The obtained solid was filtrered and washed with hexane (10 ml). The wet material was dried under vacuum to afford l-(2-2-difluoro-benzo[l,3]dioxol-5- yl)-cyclopropanecarboxylic acid amide (7.5 g , 61.3% yield)
Example 4:
Preparation of tert-butyl-3-(6-chloro-3-methylpyridine-2-yl)benzoate
a) Preparation of tert-butyl-3(3-methylpyridin-2-yl)benzoate
10 g of 2-bromo-3-methyl pyridine was dissolved in 120 ml of toluene. 38.5 g of potassium carbonate was added followed by 35 ml of water and the mixture heated to 65 °C under N2 atm for 1 hour. 13.55 g (t-butoxycarbonyl)phenylboronic acid and 0.72 g Pd(dppf)Cl2 were added. The reaction mixture was heated to 80 °C. After completion of reaction, the reaction mass was cooled, 35 ml water was added and stirred for 15 min. The layers were separated. The organic layer was washed with 35 ml water and extracted
with 230 ml 10% methane sulfonic acid. The aqueous layer was basified with 50% NaOH and extracted with 100 ml ethyl acetate. The organic layer was concentrated under vacuum to afford 13 g crude tert-butyl-3(3-methylpyridin-2-yl)benzoate (83.3 % yield). b) Preparation of 2-(3-(tert-butoxycarbonyl)phenyl)-3-methylpyridine-l-oxide
13 g of tert-butyl-3(3-methylpyridin-2-yl)benzoate was dissolved in 80 ml ethyl acetate, then 4 ml water and 15 g ureahydrogen peroxide were added. 22 g of phthalic anhydride was added portion wise and the reaction temperature was maintained below 45 °C. The reaction mixture was heated to 45 °C and stirred for 4 hours. After completion of reaction, the reaction mass was cooled to room temperature. 100 ml of 10% sodium sulphite solution was added slowly and the reaction mixture was stirred for 30 minutes. The layers were separated and organic layer was washed with 100 ml 10% sodium carbonate and 100 ml 10% sodium chloride solution. The organic phase is then filtered and concentrated under vacuum to afford 2-(3-(tert-butoxycarbonyl)phenyl)-3- methylpyridine- 1 -oxide (13 g , 94.8 %). c) Preparation of tert-butyl-3-(6-Chloro-3-methylpyridine-2-yl)benzoate
10 g of 2-(3-(tert-butoxycarbonyl)phenyl)-3-methylpyridine-l -oxide was dissolved in 50 ml dichloromethane and 8.8 g triethylamine (TEA) was added. To the reaction mass 13.6 ml phosphorous oxychloride solution in 20 ml dichloromethane was added slowly at 0-5 °C. The reaction mass was stirred for 2-3 hours at room temperature. After the completion of reaction, chilled water was added and the reaction mass was stirred for 10 min. The layers were separated, and the aqueous layer was extracted with dichloromethane. The organic layer washed with water. The organic layer was concentrated under reduced pressure and purified by column chromatography by using 10% ethyl acetate in hexane to afford tert-butyl-3-(6-chloro-3-methylpyridine-2- yl)benzoate (6 g , 56.6 % yield).
Example 5:
Preparation of 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropane carboxamido)-3-methylpyridin-2-yl)-t-butylbenzoate
A mixture 9.6 g l-(2-2-difluoro-benzo[l,3]dioxol-5-yl)-cyclopropanecarboxylic acid amide, 160 mg palladium acetate, 580 mg Xantphos, and 16.5 g cesium carbonate in 50 ml 1,4-dioxane were stirred for 10 min. To the reaction mixture, tert-butyl-3-(6-chloro-3- methylpyridine-2-yl)benzoate solution (10 g in 50 ml 1,4-dioxane) was added at room temperature. The reaction mixture was heated to reflux for 15 hours. After completion of the reaction, the reaction mass was cooled to room temperature. The reaction mass was filtered through Hyflo and washed with 10 ml 1,4-dioxane. Filtrate was isolated completely under vacuum. 100 ml toluene was then added and the reaction mass was stirred for 10 min. The reaction mass was washed with 20 ml of water. Toluene was distilled out completely under vacuum to afford 16 g of crude 3-(6-(l-(2,2- difluorobenzo[d] [ 1 ,3]dioxol-5-yl)cyclopropane carboxamido) -3-methylpyridin-2-yl)-t- butylbenzoate ( 95.8% yield).
Example 6:
Preparation of 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropane carboxamido)-3-methylpyridin-2-yl)-t-butylbenzoate
A mixture of 9.6 g l-(2-2-difluoro-benzo[l,3]dioxol-5-yl)-cyclopropanecarboxylic acid amide, 400 mg palladium acetate, 2 g BINAP[(±)-2,2'-bis(diphenylphosphino)-l,l'- binaphthalene ], and 5 g sodium tertiary butoxide in 100 ml toluene were stirred for 10 min. To the reaction mixture tert-butyl-3-(6-chloro-3-methylpyridine-2-yl)benzoate solution (10 g in 50 ml toluene) was slowly added at room temperature. The reaction mixture was heated to reflux for 15 hours. After the completion of reaction, reaction mass was cooled to room temperature and filtered through Hyflo. Filtrate was washed with water, distilled out toluene completely under vacuum to afford 16 g of crude 3-(6- ( 1 -(2,2-difluorobenzo[d] [ 1 ,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2- yl)-t-butylbenzoate ( 95.8% yield)
Example 7:
Preparation of N-(6-chloro-5-methylpyridine--2-yl)-l-(2,2difluorobenzo[d][l,3] dioxol-5-yl)cyclopropanecarboximide
10 g of N-(5-methyl-l-oxy-pyridin-2-yl)-l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxamide was dissolved in 50 ml dichloromethane and 3.5 g triethylamine (TEA) was added. To the reaction mass, 5.3 g phosphorous oxychloride was added slowly at 0-5°C. The reaction mass was stirred for 2-3 hours at room temperature. After completion of reaction, 50 ml of chilled water was added slowly and the reaction mass was stirred for 10 min. The layers were separated, and the aqueous layer was extracted with 25 ml dichloromethane. The organic layer was washed with water, concentrated under reduced pressure, and purified by column chromatography by using 10% ethyl acetate in hexane to afforded N-(6-chloro-5-methylpyridin-2-yl)-l-(2,2- difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamide (2 g , 18 % yield). Example 8:
Preparation of Lumacaftor
10 g N-(6-chloro-5-methylpyridin-2-yl)- 1 -(2,2-difluorobenzo[d] [ 1 ,3]dioxol-5- yl)cyclopropanecarboxamide was dissolved in 30 ml of N,N-dimethylformamide. To the solution, 6.8 g of 3-boronobenzoic acid, 50 ml of aqueous potassium carbonate solution and 2.1 g Pd(dppf)Cl2 were added and the reaction mass was heated to 150 °C for 15-30 min. The reaction mixture was filtered and purified by column chromatography 10% EtOAC in hexane to yield lumacaftor.
Example 9:
Preparation of Lumacaftor
A solution of 16 g of 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropane carboxamido)-3-methylpyridin-2-yl)-t-butylbenzoate in 48 ml formic acid was heated to 75-80 °C and maintained for 8 hours. After the completion of reaction, the reaction mixture was cooled to room temperature, 100 ml water was added slowly to the reaction mixture which was heated to 50 °C and stirred for 2 hours. The reaction mixture was further heated to 75-80 °C and stirred for 2 hours. The reaction mass was cooled to room
temperature, and the product was filtered and washed with water. The wet material was dried in a vacuum oven at 60 °C to afford lumacaftor. (12.g , 85% yield)
Example 10:
Preparation of Lumacaftor
To a slurry of 15 g of 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)-t-butylbenzoate in 48 ml acetonitrile was added 12.5 ml water, followed by concentrated 12.5 ml aqueous HC1. The mixture was heated to 45-50 °C and maintained for 48 hours. After completion of reaction, the reaction mixture was cooled to room temperature, and 20 ml of water was added. The reaction mixture was stirred for 1 hour. The resulting product was filtered and washed with 5 ml acetonitrile. The wet material was dried in a vacuum oven at 60 °C to afford lumacaftor hydrochloride.
A slurry of 12.0 g of lumacaftor hydrochloride in 120 ml water was stirred for 30 hours at ambient temperature. The product was filtered and washed with water. The solid was dried under vacuum at 60 °C to afford lumacaftor (11 g,85% yield).
Claims
1. A process for the preparation of lumacaftor (compound of formula I) or pharmaceutically acceptable salts thereof
Formula I
comprising the steps of:
a) treating a compound of formula II, with a compound of formula III to give a compound of formula la, wherein X is a halogen and R is a hydrogen or a carboxylic acid protecting group
Formula III
Formula la . an(j
b) optionally deprotecting the formula la to produce lumacaftor.
2. The process according to claim 1, wherein step a) is carried out in presence of a catalyst, a ligand, a base, and a solvent.
3. The process according to claim 2, wherein the catalyst is selected from the group consisting of Pd(dba)2, Pd2(dba)3, Pd(OAc)2,Pd(dppf)Cl2, Pd(C3H5)Cl, Pd(PPh3)4, and mixtures thereof.
4. The process according to claim 2, wherein the ligand is selected from the group consisting of Xantphos, BINAP, DPPF, DPEphos, Fu's salt, DavePhos, t- BuDavePhos, triphenylphosphine, trialkyl phosphines, and mixtures thereof.
5. The process according to claim 2, wherein the base is an organic base, an inorganic base, or mixtures thereof.
6. The process according to claim 5, wherein the organic base is selected from the group consisting of pyridine, trimethylamine, N, N-diisopropylethylamine, and mxitures thereof.
7. The process according to claim 5, wherein the inorganic base is selected from the group consisting of alkaline metal hydroxide, alkaline metal bicarbonate, alkaline metal carbonate, alkaline alkoxide, and mixtures thereof.
8. The process according to claim 5, wherein the inorganic base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide,
potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof.
9. The process according to claim 2, wherein the solvent is a non-polar solvent, a polar aprotic solvent, a polar protic solvent, or mixtures thereof.
10. The process according to claim 9, wherein the non-polar solvent is selected from the group consisting of 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether (MTBE), dichloromethane, and mixtures thereof.
11. The process according to claim 9, wherein the aprotic solvent is selected from the group consisting of acetone, acetonitrile, methyl ethyl ketone, methyl isobutyl ketone, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, N-methylpyrrolidinone, dimethylsulf oxide, 1 ,2-dimethoxyethane and mixtures thereof.
12. The process according to claim 9, wherein the polar protic solvent is selected from the group consisting of water, methanol, ethanol, isopropyl alcohol, n-butanol, and mixtures thereof.
13. The process according to claim 1, wherein the deprotection is carried out in presence of an acid and a solvent.
14. The process according to claim 13, wherein the acid is an organic acid, an inorganic acid, or mixtures thereof.
15. The process according to claim 14, wherein the organic acid is selected from the group consisting of formic acid, acetic acid, propanoic acid, tartaric acid, oxalic acid, maleic acid, mandellic acid, malonic acid, methane sulphonic acid, p-toluene sulphonic acid or trifluoroacetic acid, benzene sulfonic acid, and mixtures thereof.
16. The process according to claim 14, wherein the inorganic acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydro iodic acid, sulphuric acid, nitric acid, boric acid, phosphoric acid, chromic acid, and mixtures thereof.
17. The process according to claim 13, wherein the solvent is a polar aprotic solvent, a polar protic solvent, or mixtures thereof.
18. The process according to claim 17, wherein the polar aprotic solvent is selected from the group consisting of acetone, acetonitrile, methyl ethyl ketone, methyl isobutyl ketone, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, N- methylpyrrolidinone , dimethylsulfoxide, 1 ,2-dimethoxyethane and mixtures thereof.
19. The process according to claim 17, wherein the polar protic solvent is selected from the group consisting of water, methanol, ethanol, isopropyl alcohol, n- butanol, and mixtures thereof.
20. A process for the preparation of lumacaftor (a compound of formula I) or pharmaceutically acceptable salts thereof
Formula I
comprising the steps of:
a) halogenating the compound of formula IV with a halogenating agent to produce a compound of formula V, wherein X is a halogen;
Formula IV Formula V
b) coupling the compound of formula V with a compound of formula VI to get a compound of formula la, wherein X is a halogen and R is a hydrogen or a
Formula V
Formula la c) optionally deprotecting the compound of formula la to give lumacaftor.
21. The process according to claim 20, wherein the halogenating agent is selected from the group consisting of phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl dibromide, oxalyl bromide, thionyl bromide, phosphorous bromide, phosphorus oxybromide, chloroacetyl chloride.
22. The process according to claim 20, wherein step a) is carried out in presence of a base and a solvent.
23. The process according to claim 22, wherein base is an organic base, an inorganic base, or mixtures thereof.
24. The process according to claim 23, wherein the organic base is selected from the group consisting of pyridine, triethylamine. N, N-diisopropylethylamine, tributyl amine, diisopropyl amine, and mixtures thereof.
25. The process according to claim 22, wherein the solvent is a non-polar solvent, a polar protic solvent, a polar protic solvent, or mixtures thereof.
26. The process according to claim 22, wherein non-polar solvent is selected from the group consisting of 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether, dichloromethane, and mixtures thereof.
27. The process according to claim 20, wherein step b) is carried out in presence of a base, a catalyst, and a solvent.
28. The process according to claim 27, wherein the catalyst is selected from the group consisting of Pd(dba)2, Pd2(dba)3, Pd(OAc)2, Pd(dppf)Cl2, Pd(PPh3)4, [Pd(C3H5)Cl]2, copper, cuprous bromide, cuprous iodide, 2,2'-bis- diphenylphosphanyl[l, l'] binaphtalenyl (rac-Binap), and mixtures thereof.
29. The process according to claim 27, wherein the base is an organic base, an inorganic base, or mixtures thereof.
30. The process according to claim 29, wherein the inorganic base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof.
31. The process according to claim 27, wherein the solvent is a polar aprotic solvent, a protic solvent, or mixtures thereof.
32. The process according to claim 31 , wherein the polar aprotic solvent is selected from the group consisting of acetone, acetonitrile, methyl ethyl ketone, methyl isobutyl ketone, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, N- methylpyrrolidinone, dimethylsulfoxide, 1 ,2-dimethoxyethane and mixtures thereof.
33. The process according to claim 20, wherein step c) is carried out in presence of an acid and a solvent.
Formula II
Formula ill ^ wherein X is a halogen and R is a hydrogen or a carboxylic acid protecting group.
Formula IV
Formula V , wherein X is a halogen.
38. A process for the preparation of a compound of formula II, comprising the steps of reacting a compound of formula lib in the presence of an ammonia source and a solvent, wherein X is a halogen.
Formula II
Formula lib
39. The process according to claim 38, wherein the ammonia source is selected from the group consisting of ammonium hydroxide, ammonia gas, ammonium acetate, ammonium formate, and mixtures thereof.
. The process according to claim 38, wherein the solvent is a non-polar solvent.
41. The process according to claim 40, wherein the non-polar solvent is selected from the group consisting of 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether, dichloromethane, and mixtures thereof.
42. The process according to claim 38, wherein the compound of formula lib is
Formula Ila
43. A process for the preparation of a compound of formula II, comprising the steps of hydrolyzing a cyano compound of formula lid to give the compound of formula II.
Formula lid Formula II
44. The process according to claim 43, wherein the hydrolyzing step is carried out in presence of an acid, a base, and optionally a peroxide.
45. The process according to claim 43, wherein the acid is an organic acid, an inorganic acid, or mixtures thereof.
46. The process according to claim 44, wherein the organic acid is selected from the group consisting of formic acid, acetic acid, propanoic acid, methane sulphonic acid, p-toluene sulphonic acid, trifluoroacetic acid, and mixtures thereof.
47. The process according to claim 44, wherein the inorganic acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulphuric acid, nitric acid, and mixtures thereof.
48. The process according to claim 44, wherein the base is an organic base, an
inorganic base, or mixtures thereof.
49. The process according to claim 48, wherein the inorganic base is an alkaline metal hydroxide, an alkaline metal bicarbonate, an alkaline metal carbonate, or an alkaline alkoxide.
50. The process according to claim 48, wherein the inorganic base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide,
potassium propoxide, sodium tert-butoxide, potassium tert-butoxide, and mixtures thereof.
51. The process according to claim 43, wherein the compound of formula lid is
Formula 11c
52. A process for the preparation of a compound of formula III, comprising the steps of halogenating a compound of formula Hid in the presence of a halogenating agent to give the compound of formula III, wherein R is hydrogen or a carboxylic acid protecting group.
Formula Hid Formula III
53. The process according to claim 52, wherein the halogenating step is carried out in thje presence of a base and a solvent.
54. The process according to claim 52, wherein halogenating agent is selected from the group consisting of phosgene, oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorous trichloride, phosphorus oxychloride, carbonyl
dibromide, oxalyl bromide, thionyl bromide, phosphorous bromide, phosphorus oxybromide, chloroacetyl chloride, methane sulfonyl chloride, benzene sulfonyl chloride, p-toluene sulfonyl chloride, and mixtures thereof.
55. The process according to claim 53, wherein the base is an organic base, an
inorganic base, or mixtures thereof.
56. The process according to claim 55, wherein the organic base is selected from the group consisting of pyridine, trimethylamine, N, N-diisopropylethylamine, and mixtures thereof.
57. The process according to claim 53, wherein the solvent is a non-polar solvent.
58. The process according to claim 57, wherein the non-polar solvent is selected from the group consisting of 1,4-dioxane, toluene, benzene, xylene, methyl t-butyl ether, dichloromethane, and mixtures thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3831CH2015 | 2015-07-27 | ||
| IN3831/CHE/2015 | 2015-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017017696A1 true WO2017017696A1 (en) | 2017-02-02 |
Family
ID=56896749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2016/050250 Ceased WO2017017696A1 (en) | 2015-07-27 | 2016-07-25 | Process for the preparation of lumacaftor |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017017696A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565814A4 (en) * | 2017-01-09 | 2020-08-19 | Laurus Labs Limited | PROCEDURE AND CRYSTALLINE FORMS OF LUMACAFTOR |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073757A1 (en) * | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| WO2009076142A2 (en) * | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| WO2011127290A2 (en) * | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
-
2016
- 2016-07-25 WO PCT/IN2016/050250 patent/WO2017017696A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073757A1 (en) * | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| WO2009076142A2 (en) * | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| WO2011127290A2 (en) * | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Non-Patent Citations (5)
| Title |
|---|
| ALEXANDRA E. GOULD ET AL: "Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 6, 24 March 2011 (2011-03-24), US, pages 1836 - 1846, XP055308132, ISSN: 0022-2623, DOI: 10.1021/jm101479y * |
| JINGJUN YIN ET AL: "PALLADIUM-CATALYZED INTERMOLECULAR COUPLING OF ARYL HALIDES AND AMIDES", ORGANIC LETTERS , 14(23), 6012-6015 CODEN: ORLEF7; ISSN: 1523-7052,, vol. 2, no. 8, 1 January 2000 (2000-01-01), pages 1101 - 1104, XP002413650, ISSN: 1523-7060, DOI: 10.1021/OL005654R * |
| REWINKEL J B M ET AL: "1-aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 9, no. 5, 8 March 1999 (1999-03-08), pages 685 - 690, XP004157594, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(99)00069-4 * |
| S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
| VEGI S R ET AL: "The first total synthesis of potent human chymase inhibitor SPF32629B via regioselective bromination and O-acylation strategy", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 51, no. 20, 19 May 2010 (2010-05-19), pages 2768 - 2770, XP027077142, ISSN: 0040-4039, [retrieved on 20100519], DOI: 10.1016/J.TETLET.2010.03.091 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565814A4 (en) * | 2017-01-09 | 2020-08-19 | Laurus Labs Limited | PROCEDURE AND CRYSTALLINE FORMS OF LUMACAFTOR |
| EP4434581A2 (en) | 2017-01-09 | 2024-09-25 | Laurus Labs Limited | Process and crystalline forms of lumacaftor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7100125B2 (en) | Process for improved preparation of ribociclib and its salts | |
| EP3712130B1 (en) | Method for synthesis of roxadustat and intermediate compounds thereof | |
| CN105283442B (en) | Method for synthesizing 1 (2 ((2,4 3,5-dimethylphenyl) is thio) phenyl) piperazine | |
| CN103702992B (en) | Method for producing tetrazole-substituted anthranilic acid diamide derivatives by reacting pyrazolic acid with anthranilic acid ester | |
| ITMI20090397A1 (en) | PROCEDURE FOR THE PREPARATION OF 6- (7 - ((1-AMINOCYCLOPROPYL) METHOSSI) -6-METOSSICHINOLIN-4-ILOSSI) -N-METHYL-1-NAFTAMIDE AND ITS INTERMEDIATES OF SYNTHESIS | |
| US8536350B2 (en) | Process for the manufacture of dronedarone | |
| KR20170021256A (en) | Method for producing fused heterocyclic compound | |
| JP6441478B2 (en) | Process for preparing disubstituted 1,4-benzenediamine and salts thereof | |
| WO2018153380A1 (en) | Preparation of velpatasvir and derivative thereof | |
| CN101528700A (en) | Process for preparing imatinib and intermediates thereof | |
| WO2010144959A1 (en) | Analogues of anti-fibrotic agents | |
| CN114698376A (en) | Biphenyl compounds as immunomodulators and preparation method and application thereof | |
| WO2017017696A1 (en) | Process for the preparation of lumacaftor | |
| CN109748902B (en) | A kind of preparation method of Anlotinib hydrochloride | |
| US20180065909A1 (en) | METHODS FOR meta-ARYLATION OF AROMATIC ALCOHOLS | |
| CN104781236B (en) | The method for preparing 2- trifluoromethyls isonicotinic acid and ester | |
| CN104447543B (en) | Synthetic method of 3-amino-7,8-difluoroquinoline and its intermediate | |
| CN110891566B (en) | Synthetic methods and synthetic intermediates | |
| CN102863341B (en) | Chemical synthesis method of (1R, 2S)-2-aryl cyclopropylamine derivative | |
| KR20180095911A (en) | Process for producing benzoxazole compound | |
| CN106632066A (en) | Benzimidazole compound and preparation method and application thereof | |
| US20140275542A1 (en) | Synthesis of a serotonin reuptake inhibitor | |
| AU2005252060A1 (en) | Method for producing 3-aminomethyltetrahydrofuran derivative | |
| KR102919305B1 (en) | Method for preparing substituted 2-[2-(phenyl)ethylamino]alkanamide derivatives | |
| WO2020042841A1 (en) | Preparation method for (1r,3s)-3-amino-1-cyclopentanol and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16763595 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16763595 Country of ref document: EP Kind code of ref document: A1 |


































